Jame Abraham, MD, Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic Cancer Institute, joins the Cancer Advances Podcast to discuss how artificial intelligence (AI) is transforming oncology care. Listen has he shares insights from Cleveland Clinic’s recent AI in healthcare conference, real-world applications such as clinical documentation and trial matching, and how AI may reshape research, patient care, and the future of cancer treatment.

Orthopedic Oncologist at Cleveland Clinic in Florida, Jorge Manrique-Succar, MD, returns to the Cancer Advances Podcast to share the latest advances in treating metastatic bone disease. Listen as Dr. Manrique talks about early intervention, advanced surgical techniques, and multidisciplinary collaboration are improving outcomes for cancer patients with skeletal-related complications.

Wen Wee Ma, MBBS, Enterprise Vice Chair for Research and Director of the Novel Cancer Therapeutics Center, joins the Cancer Advances Podcast to discuss a phase 1 trial of KB707 presented at ASCO 2025. This innovative therapy delivers IL-2 and IL-12 directly to the lungs through inhalation, aiming to minimize side effects and improve outcomes for patients with lung tumors. Dr. Ma shares early trial results and what they could mean for the future of cancer treatment.

Kelley Kozma, DO, MS, Medical Director for Oncology at Cleveland Clinic Martin Health in Florida, to discuss how targeted therapies, next generation sequencing, and personalized medicine are transforming breast cancer care. Listen as Dr. Kozma shares how innovations like HER2-low targeting, liquid biopsy, and circulating tumor DNA are helping clinicians tailor treatments and improve outcomes.

Brian Burkey, MD, MEd, Interim Director of the Scully Walsh Cancer Center and Division Chair of Otolaryngology Head and Neck Surgery at Cleveland Clinic in Florida, joins the Cancer Advances Podcast to talk about management strategies for clinically node-negative salivary gland cancer. Listen as Dr. Burkey highlights findings from an outcomes study and share strategies to better identify high-risk patients who may benefit from more aggressive treatment.

George Stark, PhD, and Christine McDonald, PhD, from Cleveland Clinic’s Lerner Research Institute, join the Cancer Advances Podcast to discuss the development of PALA as a novel immunostimulatory agent in oncology. Listen as they highlight promising preclinical data across multiple tumor types, potential for combination therapies and plans for clinical translation, including topical use for skin cancer.

The Cancer Advances Podcast welcomes back Sudha Amarnath, MD, a Radiation Oncologist and Co-Director of the Gynecologic Cancer Program at Cleveland Clinic to discuss the potential of self-collected HPV tests to expand access to cervical cancer screening. Listen as Dr. Amarnath shares insights into how these tests work, their FDA approval, and their potential to reach underserved populations who face barriers to traditional screening methods.

Megan Kruse, MD, a Medical Oncologist and Director of the Clinical Breast Cancer Research Program at Cleveland Clinic joins the Cancer Advances Podcast to share breast cancer research highlights from the 2025 ASCO Conference. She discusses key findings from studies in metastatic hormone receptor-positive, triple-negative, and HER2-positive breast cancer, including potential practice-changing data on oral SERDs, antibody-drug conjugates, and ctDNA testing.

Rafael Arteta-Bulos, MD, a Genitourinary Medical Oncologist at Cleveland Clinic’s Maroone Cancer Center in Weston, Florida, joins the Cancer Advances Podcast to discuss the use of virtual reality in the care of patients with cancer. Dr. Arteta shares how this emerging technology is being studied as a supportive tool to reduce distress, anxiety, and improve overall well-being during chemotherapy.

Laura Bukavina, MD, MPH, a Urologic Oncologist and Translational Research Lead for genitourinary oncology at Cleveland Clinic joins the Cancer Advances Podcast to talk about strategies to improve the survivorship experience for women with bladder cancer, including treatment advances, quality-of-life considerations and encouraging open conversations to drive better survivorship programs.